Credits Available: 4.75 hours of AMA PRA Category 1 Credit

Description: Patients who are living with obesity or overweight may seek care with an endocrinologist for other comorbidities, some of which may be directly linked to their weight. Weight reduction and management using pharmacotherapy, including GLP-1 RAs, can be a useful strategy to help patients improve not only their weight but also their metabolic health. Through this program, endocrinologists will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs, especially if they have other comorbidities, and apply clinical trial findings to everyday patient care. They will also enhance their understanding of strategies which can improve both patient adherence and payor authorization/approval.

Obesity Medicine Association Logo

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Endocrinology

Vivian Fonseca

Tulane University
Professor

Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, Assistant Dean for Clinical Research, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana.. He is a Past President for Science and Medicine of the American Diabetes Association (2012), and has served on the ADA Board of Directors and several committees. He has served on the Board of Directors of the American Association of Clinical Endocrinologists (AACE), and the Board of Trustees of the American College of Endocrinology. He has served on committees writing guidelines for both organizations. He has held a leadership role and served on various committees in several other organizations including the American Board of Internal Medicine. He has received several awards including Banting Medal for Leadership and Service from The American Diabetes Association, the Seale - Harris award from the Southern Medical Association, and the Gerald Reaven award from the World Congress in Insulin Resistance. He has received several teaching awards and was elected to the Alpha Omega Alpha Honor Medical Society and has been listed for several years among the Best Doctors in the USA and for several years rated by Expertscape among the top 10 experts in Diabetes worldwide. Dr. Fonseca is a fellow of the Royal College of Physicians (London).
He plays a significant role in Clinical Research as Assistant Dean at Tulane University, and in its partnership with the Louisiana Clinical and Translational Science (LACaTS) Program. Dr Fonseca has served as Associate Director of the Aging and Cardiometabolic COBREs and a mentor and committee member in BIRCWH. He a strong interest in facilitating clinical research and developing the next generation of translational researchers. He is the Medical Director of the Tulane Clinical Trials Unit and Director of the Research Professional Development Core, which runs the Masters in Science in Clinical Research degree course.
He has had several roles as editor of scientific journals including current Editor in chief of Endocrine Research, Editor in chief of Diabetes Care, (2007-2011 having formerly been associate editor; Editor in Chief of the Journal of the Metabolic Syndrome (2002-2006); and Editor in Chief of the Journal of Diabetes and its Complications (2012-2022) and Endocrine Research (from 2023). He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism, and is an ad hoc reviewer for several other journals, including New England Journal of Medicine, Lancet, JAMA, Diabetes, etc.
Dr. Fonseca’s research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease, particularly on the role of inflammation and other novel risk factors. He has a research program evaluating inflammation in diabetes, and using technology to improve diabetes care in underprivileged populations, especially the development and use of a novel diabetes risk engine (BRAVO) in clinical practice. He is Co – PI of REACHNET a large network that conducts research utilizing electronic health records of over 2 million people across several states. He is the site PI of several large national research programs including 1. the All of Us Program, 2. COVID related studies – N3C utilizing EMR data about COVID and the RECOVER study which will evaluate long term COVID complications in a large cohort.
Dr. Fonseca has lectured in the United States and abroad. He has published over 500 papers and review articles. He is the editor of the text book “Clinical Diabetes: Translating Research into Practice” (El Sevier) and several monographs and book chapters.